Enso Ventures

Cognitive Geology Ltd develops geological modeling software for oilfield geologists. The company helps geologist identify and sequentially remove the effects of the various geological processes. The company was founded in 2014 and is headquartered in Edinburgh, Midlothian, United Kingdom.

Neurovia, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, founded in 2013. The company focuses on developing therapies for neurological disorders, specifically targeting unmet medical needs associated with X-linked adrenoleukodystrophy (X-ALD). Neurovia's primary objective is to provide a treatment that can halt the progression of neurological deficits caused by this rare genetic disease. The company has developed a selective thyromimetic agent aimed at improving the quality of life for patients suffering from X-ALD.

UltraSoC Technologies Ltd. specializes in semiconductor intellectual property (IP) focused on system monitoring, analysis, and optimization for advanced systems-on-chip (SoC) devices. Founded in 2005 and headquartered in Cambridge, UK, the company offers a comprehensive toolkit that includes dedicated and optimized IP, as well as configurable modules for design-time and run-time adjustment. Its technology facilitates non-intrusive, wire-speed monitoring of SoC behavior, allowing engineers to understand complex interactions among on-chip subsystems, buses, and software. This capability accelerates development and minimizes risks associated with SoC design. UltraSoC's solutions are applied in various contexts, including SoC debugging, analytics, optimization, and security applications, thereby enhancing the efficiency of embedded systems development. The company operates as a subsidiary of Siemens Aktiengesellschaft.

Cavion LLC is a clinical-stage pharmaceutical company focused on developing therapies for neurological and rare genetic diseases by modulating T-type calcium channels (Cav3). The company’s lead product, CX-8998, targets these channels in the nervous system, and Cavion aims to deliver innovative non-opioid treatments for conditions such as neuropathic pain, essential tremor, Parkinson’s disease, epilepsy, and Angelman syndrome. Founded in 2003 and based in Charlottesville, Virginia, with an additional office in Cambridge, Massachusetts, Cavion was previously known as Tau Therapeutics LLC until its name change in 2014. The company is notable for being the first to target Cav3 ion channels in the treatment of solid tumors, with ongoing Phase 1 clinical trials investigating its potential in brain cancer. Cavion's approach leverages advanced chemistry and clinical expertise to enhance the efficacy of existing therapies, such as chemotherapy and radiation, against solid tumor cancers. As of August 2019, Cavion operates as a subsidiary of Jazz Pharmaceuticals plc.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.

SRJ Limited, founded in 2011 and headquartered in St Helier, Jersey, specializes in the manufacturing and distribution of weld-free coupling and leak containment solutions for pipeline and process pipework systems. The company's product range includes various connectors such as slip joints, digital couplings, and valve connectors, designed for diverse applications across industries including oil and gas, desalination, mining, utilities, shipping, and power generation. SRJ Limited also offers asset integrity management consulting services, assisting clients in the effective management of containment systems. The company holds an exclusive license for the innovative Snap Ring Joint (SRJ) technology, which has received Type Approval from Lloyds Register and ABS for use in hydrocarbon services. With a strong focus on research and development, SRJ Limited aims to address the growing global demand for reliable pipeline connection solutions.

Egalet is a specialty pharmaceutical company that develops pain management products. The company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.

Picodeon provides thin film deposition technology for various applications. The company is a privately owned Nordic company with corporate headquarters in Helsinki, Finland. Their R&D is supported by governmental contracts. They have an application laboratory in Kuopio, Finland, which is used for their own R&D and customer pilot projects. Their sales office is in Malmö, Sweden.

Cellectar Biosciences is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of cancer therapies. Based in Florham Park, New Jersey, the company focuses on its proprietary phospholipid drug conjugate (PDC) platform, which aims to enhance the targeted delivery of cancer treatments while minimizing side effects. Its lead product candidate, CLR 131, is currently undergoing Phase II clinical trials for relapsed or refractory multiple myeloma and various B-cell malignancies. In addition, Cellectar is developing CLR 1900, a chemotherapeutic program aimed at solid tumors. The company also collaborates with several partners to advance various PDC programs, including those targeting specific cancer types. Originally established in 2002 as Novelos Therapeutics, Inc., Cellectar Biosciences has evolved through various name changes and strategic initiatives to focus on innovative cancer treatment solutions.

Cambridge Nanotherm Limited specializes in the development and commercialization of innovative nano-ceramic technology for the electronics industry. Founded in 2010 and located in Haverhill, United Kingdom, the company offers a unique portfolio that includes its NANOTHERM metal-backed printed circuit board and chip-on-heat sink designs, particularly for LED light engines. The NANOTHERM technology utilizes a patented nano-ceramic coating process to create a dielectric layer directly on aluminum substrates, enhancing thermal conductivity and dielectric strength. This advanced thermal management solution addresses the needs of high-powered electronics and LED applications, positioning Cambridge Nanotherm as a leader in efficient thermal management technologies.

Carbodeon Ltd Oy is a Finnish company specializing in the development and manufacture of carbon-based nanomaterials. Established in 2006 and based in Vantaa, the company produces graphitic carbon nitride, which is utilized in various applications including biocompatible coatings, tribological coatings, chemically inert coatings, insulators, and energy storage solutions. Carbodeon also offers nanodiamonds designed for diverse uses such as polishing, electroplating, lubricants, and enhancing plastics and rubber. Their products, marketed under the names uDiamond and Nicanite, focus on improving the surface properties of materials to increase durability and performance. As a subsidiary of Enso Holding Ltd, Carbodeon continues to innovate in the field of nanotechnology, providing solutions that meet the growing demands of industrial applications.